ArticleEJNMMI physics2018
Comparison of radiobiological parameters for
Article in EJNMMI physics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 34 citations in OpenAlex.
- Theranostics in Radiation Medicine: Integrating Radiopharmaceutical Therapy and External-Beam Radiotherapy.Journal of clinical medicine · 2026Review
- Cellular responses to targeted radionuclide therapy: rethinking radiobiology under continuous low dose rates.Frontiers in oncology · 2026Review
- Systemic effects ofEuropean journal of nuclear medicine and molecular imaging · 2025Article
- Theranostic Radioembolization: Radiation Dosimetry-Guided Treatment Planning and Delivery.World journal of nuclear medicine · 2025Review
- Article
- A mathematical model for the investigation of combined treatment of radiopharmaceutical therapy and PARP inhibitors.European journal of nuclear medicine and molecular imaging · 2025Article
- A proof-of-concept study of personalized dosimetry for targeted radioligand therapy using pre-treatment diagnostic dynamic PET/CT and Monte Carlo simulation.Frontiers in oncology · 2025Article
- The role of biomarkers and dosimetry parameters in overall and progression free survival prediction for patients treated with personalizedEuropean journal of nuclear medicine and molecular imaging · 2024Article
- Deciphering the effects of radiopharmaceutical therapy in the tumor microenvironment of prostate cancer: an in-silico exploration with spatial transcriptomics.Theranostics · 2024Article
- Understanding the Radiobiological Mechanisms Induced byInternational journal of molecular sciences · 2022Article
- A Review on Tumor Control Probability (TCP) and Preclinical Dosimetry in Targeted Radionuclide Therapy (TRT).Pharmaceutics · 2022Review
- Towards personalised dosimetry in patients with liver malignancy treated withEJNMMI physics · 2022Article
- Small-scale dosimetry for alpha particleEJNMMI physics · 2022Article
- Modelling a new approach for radio-ablation after resection of breast ductal carcinoma in-situ based on the BAT-90 medical device.Scientific reports · 2022Article
- Individualised dosimetry and safety of SIRT for intrahepatic cholangiocarcinoma.EJNMMI physics · 2021Article
- Evaluation of the PSMA-Binding LigandInternational journal of molecular sciences · 2021Article
- Quantitative PET in the 2020s: a roadmap.Physics in medicine and biology · 2021Article
- Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer.Cancers · 2021Review
- HIF2alpha-Associated Pseudohypoxia Promotes Radioresistance in Pheochromocytoma: Insights from 3D Models.Cancers · 2021Article
- A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Therapeutic Isotopes.International journal of nanomedicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundDose rate variation is a critical factor affecting radionuclide therapy (RNT) efficacy. Relatively few studies to date have investigated the dose rate effect in RNT. Therefore, the aim of this study was to benchmark
resultsThree human colorectal carcinoma (CRC) cell lines (HT29, HCT116, SW48) were exposed to
conclusionThese results demonstrate that the efficacy of RNT is dependent on the initial dose rate at which radiation is delivered. Therefore, for a relatively long half-life radionuclide such as
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.